FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035264955> ?p ?o ?g. }

• W3035264955 endingPage "104512" @default.
• W3035264955 startingPage "104512" @default.
• W3035264955 abstract "There is an urgent need for reliable high-throughput serological assays for the management of the ongoing COVID-19 pandemic. Preferably, the performance of serological tests for a novel virus should be determined with clinical specimens against a gold standard, i.e. virus neutralisation. We compared the performance of six commercial immunoassays for the detection of SARS-COV-2 IgG, IgA and IgM antibodies, including four automated assays [Abbott SARS-COV-2 IgG (CE marked), Diasorin Liaison® SARS-COV-2 S1/S2 IgG (research use only, RUO), and Euroimmun SARS-COV-2 IgG and IgA (CE marked)], and two rapid lateral flow (immunocromatographic) tests [Acro Biotech 2019-nCoV IgG/IgM (CE marked) and Xiamen Biotime Biotechnology SARS-COV-2 IgG/IgM (CE marked)] with a microneutralisation test (MNT). Two specimen panels from serum samples sent to Helsinki University Hospital Laboratory (HUSLAB) were compiled: the patient panel (N=70) included sera from PCR confirmed COVID-19 patients, and the negative panel (N=81) included sera sent for screening of autoimmune diseases and respiratory virus antibodies in 2018 and 2019. The MNT was carried out for all COVID-19 samples (70 serum samples, 62 individuals) and for 53 samples from the negative panel. Forty-one out of 62 COVID-19 patients showed neutralising antibodies.The specificity and sensitivity values of the commercial tests against MNT, respectively, were as follows: 95.1 %/80.5 % (Abbott Architect SARS-CoV-2 IgG), 94.9 %/43.8 % (Diasorin Liaison SARS-CoV-2 IgG; RUO), 68.3 %/87.8 % (Euroimmun SARS-CoV-2 IgA), 86.6 %/70.7 % (Euroimmun SARS-CoV-2 IgG), 74.4 %/56.1 % (Acro 2019-nCoV IgG), 69.5 %/46.3 % (Acro 2019-nCoV IgM), 97.5 %/71.9 % (Xiamen Biotime SARS-CoV-2 IgG), and 88.8 %/81.3 % (Xiamen Biotime SARS-CoV-2 IgM). This study shows variable performance values. Laboratories should carefully consider their testing process, such as a two-tier approach, in order to optimize the overall performance of SARS- CoV-2 serodiagnostics." @default.
• W3035264955 created "2020-06-19" @default.
• W3035264955 creator A5013400618 @default.
• W3035264955 creator A5023869007 @default.
• W3035264955 creator A5026241120 @default.
• W3035264955 creator A5048581711 @default.
• W3035264955 creator A5057256001 @default.
• W3035264955 creator A5061970583 @default.
• W3035264955 creator A5064367620 @default.
• W3035264955 creator A5079133618 @default.
• W3035264955 creator A5081442384 @default.
• W3035264955 creator A5084951688 @default.
• W3035264955 date "2020-08-01" @default.
• W3035264955 modified "2023-10-18" @default.
• W3035264955 title "Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation" @default.
• W3035264955 cites W1967889080 @default.
• W3035264955 cites W1971740900 @default.
• W3035264955 cites W2790456219 @default.
• W3035264955 cites W3001195213 @default.
• W3035264955 cites W3011017798 @default.
• W3035264955 cites W3011976215 @default.
• W3035264955 cites W3013985547 @default.
• W3035264955 cites W3014518605 @default.
• W3035264955 cites W3014721277 @default.
• W3035264955 cites W3015940872 @default.
• W3035264955 cites W3021590963 @default.
• W3035264955 cites W3023975850 @default.
• W3035264955 doi "https://doi.org/10.1016/j.jcv.2020.104512" @default.
• W3035264955 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7295517" @default.
• W3035264955 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32563180" @default.
• W3035264955 hasPublicationYear "2020" @default.
• W3035264955 type Work @default.
• W3035264955 sameAs 3035264955 @default.
• W3035264955 citedByCount "178" @default.
• W3035264955 countsByYear W30352649552020 @default.
• W3035264955 countsByYear W30352649552021 @default.
• W3035264955 countsByYear W30352649552022 @default.
• W3035264955 countsByYear W30352649552023 @default.
• W3035264955 crossrefType "journal-article" @default.
• W3035264955 hasAuthorship W3035264955A5013400618 @default.
• W3035264955 hasAuthorship W3035264955A5023869007 @default.
• W3035264955 hasAuthorship W3035264955A5026241120 @default.
• W3035264955 hasAuthorship W3035264955A5048581711 @default.
• W3035264955 hasAuthorship W3035264955A5057256001 @default.
• W3035264955 hasAuthorship W3035264955A5061970583 @default.
• W3035264955 hasAuthorship W3035264955A5064367620 @default.
• W3035264955 hasAuthorship W3035264955A5079133618 @default.
• W3035264955 hasAuthorship W3035264955A5081442384 @default.
• W3035264955 hasAuthorship W3035264955A5084951688 @default.
• W3035264955 hasBestOaLocation W30352649551 @default.
• W3035264955 hasConcept C116675565 @default.
• W3035264955 hasConcept C126322002 @default.
• W3035264955 hasConcept C159047783 @default.
• W3035264955 hasConcept C159654299 @default.
• W3035264955 hasConcept C203014093 @default.
• W3035264955 hasConcept C2522874641 @default.
• W3035264955 hasConcept C2779134260 @default.
• W3035264955 hasConcept C2780898057 @default.
• W3035264955 hasConcept C3006700255 @default.
• W3035264955 hasConcept C3007834351 @default.
• W3035264955 hasConcept C3008058167 @default.
• W3035264955 hasConcept C40993552 @default.
• W3035264955 hasConcept C45189115 @default.
• W3035264955 hasConcept C524204448 @default.
• W3035264955 hasConcept C71924100 @default.
• W3035264955 hasConceptScore W3035264955C116675565 @default.
• W3035264955 hasConceptScore W3035264955C126322002 @default.
• W3035264955 hasConceptScore W3035264955C159047783 @default.
• W3035264955 hasConceptScore W3035264955C159654299 @default.
• W3035264955 hasConceptScore W3035264955C203014093 @default.
• W3035264955 hasConceptScore W3035264955C2522874641 @default.
• W3035264955 hasConceptScore W3035264955C2779134260 @default.
• W3035264955 hasConceptScore W3035264955C2780898057 @default.
• W3035264955 hasConceptScore W3035264955C3006700255 @default.
• W3035264955 hasConceptScore W3035264955C3007834351 @default.
• W3035264955 hasConceptScore W3035264955C3008058167 @default.
• W3035264955 hasConceptScore W3035264955C40993552 @default.
• W3035264955 hasConceptScore W3035264955C45189115 @default.
• W3035264955 hasConceptScore W3035264955C524204448 @default.
• W3035264955 hasConceptScore W3035264955C71924100 @default.
• W3035264955 hasLocation W30352649551 @default.
• W3035264955 hasLocation W30352649552 @default.
• W3035264955 hasLocation W30352649553 @default.
• W3035264955 hasLocation W30352649554 @default.
• W3035264955 hasOpenAccess W3035264955 @default.
• W3035264955 hasPrimaryLocation W30352649551 @default.
• W3035264955 hasRelatedWork W3005417802 @default.
• W3035264955 hasRelatedWork W3007868867 @default.
• W3035264955 hasRelatedWork W3009669391 @default.
• W3035264955 hasRelatedWork W3018906908 @default.
• W3035264955 hasRelatedWork W3084498529 @default.
• W3035264955 hasRelatedWork W3113664224 @default.
• W3035264955 hasRelatedWork W4200329650 @default.
• W3035264955 hasRelatedWork W4205317059 @default.
• W3035264955 hasRelatedWork W4206669628 @default.
• W3035264955 hasRelatedWork W3127156785 @default.
• W3035264955 hasVolume "129" @default.
• W3035264955 isParatext "false" @default.

• next